GC Biopharma's liquid biopsy and genomic analysis subsidiary, GC Genome, announced on the 27th that it has signed a supply contract for the non-invasive prenatal test 'G-NIPT' with Vollwert Medical LLC, a medical device and healthcare solution distribution company based in the United Arab Emirates. G-NIPT is a test that detects fetal DNA present in the mother's blood to confirm chromosomal abnormalities and was independently developed by GC Genome using next-generation sequencing (NGS) technology. By being the first to introduce AI technology and the concept of fragment distance (FD), it significantly improved detection accuracy and reliability compared to existing methods. With this supply contract, GC Genome aims to enhance its brand awareness in the United Arab Emirates and expand its market share in the medium to long term.
Ildong Pharmaceutical Group's health functional food subsidiary, Ildong BioScience, noted on the 27th that it participated in 'Vita Foods Europe 2025' held in Barcelona, Spain, to promote its functional materials and explore opportunities for global expansion. During the event, Ildong BioScience showcased its functional materials as well as its quadruple coating processing technology, highlighting its competitiveness in the probiotics and postbiotics sectors. Additionally, it held partnering meetings with multiple global companies to explore possibilities for collaboration and business partnerships in overseas market development.
Hanmi Pharmaceutical announced on the 27th that it has newly launched a topical treatment for onychomycosis (fungal nail infection), 'Muzonalmax Solution,' containing terbinafine hydrochloride. This product is the first 'first generic' topical medication with a different active ingredient than existing products, and it is the first such treatment for onychomycosis to be released in South Korea. Most of the currently available topical treatments for onychomycosis in South Korea use 'ciclopirox' as the main ingredient. Hanmi Pharmaceutical's 'Muzonalmax Solution' is the first generic topical treatment for onychomycosis with 'terbinafine hydrochloride' as the main ingredient. Antifungals can lead to resistance problems, where the treatment effect decreases if the same ingredient is used for an extended period, and the company expects that Muzonalmax Solution will provide a new alternative for patients who have developed resistance to existing treatments.
HLB Life Science's subsidiary HLB Cell announced on the 27th that its next-generation surgical hemostatic agent 'BleeFix®' has demonstrated effects equal to or greater than existing hemostatic agents in a confirmatory clinical trial corresponding to Phase 3. This achievement comes three years after the start of the confirmatory clinical trial. The trial was a multicenter, randomized, single-blind, active-controlled non-inferiority comparison study conducted on 134 patients with persistent exudative bleeding after primary hemostasis during liver resection. The interim analysis showed a 'success rate of hemostasis within 5 minutes' of 98.5%, significantly demonstrating non-inferiority. Furthermore, the effectiveness evaluation was carried out by independent third-party evaluators to ensure the objectivity and reliability of the assessment.
i-SENS announced on the 27th that it received the Minister of Health and Welfare Award at the 30th anniversary ceremony of the Korean Diabetes Association. i-SENS was recognized for its contributions to improving awareness and prevention of diabetes and was selected as a 'Public Education Contributor on Diabetes,' receiving the honor of the Minister of Health and Welfare Award. As part of its ESG management practices, i-SENS has continuously engaged in various social contribution activities in cooperation with the Korean Diabetes Association, including providing free blood glucose tests to the entire nation, the 'Understanding My Blood Sugar and My Family's Blood Sugar' campaign, and diabetes education camps, contributing to the improvement of awareness and prevention of diabetes.
Noel announced on the 27th that it has completed the registration of three AI-based software medical devices and cartridges for the MyLab platform in the Swiss market. With this, Noel has expanded its export routes throughout Europe, including the European Union (EU), the United Kingdom, and Switzerland. Noel registered the entire MyLab product line with Swissmedic and obtained official distribution approval. The registered products include the MyLab platform (miLab™ Platform), AI-based software and cartridges for cervical cytology examination, blood analysis, and malaria testing (miLab™ Cartridge CER, miLab™ Cartridge BCM, miLab™ Cartridge MAL), as well as the fixative solution (SafeFix™), covering the entire product line of Noel.
Coreline Soft announced on the 27th that it has been selected as the sole supplier of artificial intelligence (AI) solutions for the national lung cancer screening initiative project 'IMPULSION,' led by the French National Cancer Center. IMPULSION is the government's first lung cancer screening initiative program conducted by the French National Cancer Institute (INCa). It will be gradually implemented across France over the next 4 to 5 years, with a target scale of 20,000 individuals. The French National Cancer Institute selected the Paris Public Hospital Group (AP-HP) and the Lyon City Hospital as the joint supervisory organizations in January of this year. After a rigorous performance evaluation of the AI software, Coreline’s product was chosen as the only candidate.
Finemedix, a company specializing in gastrointestinal endoscopic instruments, announced on the 27th that its endoscopic hemostatic device 'Clear-Hemograsper' has received medical device item approval from the U.S. Food and Drug Administration (FDA). Finemedix's Clear-Hemograsper is an endoscopic hemostatic device that uses high-frequency current to coagulate exposed vascular areas in the event of gastrointestinal bleeding, making it the first domestic product to achieve localization. Finemedix previously introduced 'Clear-Hemograsper' and 'Clear-Hemostat,' both of which have since been commercialized domestically. The company is currently exporting to Europe and Asia and plans to expand exports to Japan and North and South America.
Hallym University Sacred Heart Hospital announced on the 27th that Professor Park Kyung-hee of the Department of Family Medicine has received a commendation from the Minister of Health and Welfare. Professor Park has conducted the 'ICAAN Project' for pediatric obesity patients over the past 10 years. More than 1,000 children and adolescents with severe obesity participated in the project and successfully reduced their weight, lowering the risk of fatty liver and metabolic diseases. Professor Park graduated from Seoul National University College of Medicine and its graduate school and has served as a research professor at a Harvard University-affiliated hospital in Israel. They are active as a commissioner of the Korean Society for the Study of Obesity in Children and Adolescents and as a member of the Korean Society for the Study of Obesity.
Soldoc, a remote medical solution company, announced on the 27th that it has been finally selected as a 'baby unicorn' company with a high potential to grow into a global unicorn. One of Soldoc's main business models, the Soldoc Partners ERP solution, provides electronic medical record (EMR) functions specialized for non-face-to-face treatment, outpatient administration, patient management, and data storage. It can be partially compatible with existing in-house EMR systems without replacing them and allow broad remote prescribing for advanced solutions such as DTx and genetic testing. Since its launch in May last year, it is currently used by more than 1,500 clinics, and plans to expand its locations to 5,000 by the end of this year.